Productivity loss and indirect costs associated with cardiovascular events and related clinical procedures

BMC Health Services Research

Volumn 15, Issue 1, 2015, Pages

  Song, Xue ^a   Quek, Ruben G W ^b   Gandra, Shravanthi R ^b   Cappell, Katherine A ^a   Fowler, Robert ^a   Cong, Ze ^c  

^a IBM WATSON HEALTH   (United States)

^b AMGEN INC   (United States)

^c ONYX PHARMACEUTICALS   (United States)

Author keywords

Absenteeism; Cardiovascular diseases; Indirect cost; Short term disability

Indexed keywords

ABSENTEEISM; ADOLESCENT; ADULT; CARDIOVASCULAR DISEASE; COST OF ILLNESS; DISABLED PERSON; ECONOMICS; EMPLOYMENT; FACTUAL DATABASE; FEMALE; HUMAN; MALE; MIDDLE AGED; PRODUCTIVITY; PROPENSITY SCORE; RISK FACTOR; UNITED STATES; YOUNG ADULT;

ABSENTEEISM; ADOLESCENT; ADULT; CARDIOVASCULAR DISEASES; COST OF ILLNESS; DATABASES, FACTUAL; DISABLED PERSONS; EFFICIENCY; EMPLOYMENT; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPENSITY SCORE; RISK FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84933515521     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/s12913-015-0925-x     Document Type: Article

References (52)

1. Tarride JE, Lim M, DesMeules M, Luo W, Burke N, O'Reilly D, et al. A review of the cost of cardiovascular disease. Can J Cardiol. 2009;25:e195-202.
2. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933-44.
3. Mensah GA, Brown DW. An overview of cardiovascular disease burden in the United States. Health Aff. 2007;26:38-48.
4. Waters DD, Brotons C, Chiang CW, Ferrieres J, Foody J, Jukema JW, et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation. 2009;120:28-34.
5. Trogdon JG, Finkelstein EA, Nwaise IA, Tangka FK, Orenstein D. The economic burden of chronic cardiovascular disease for major insurers. Health Promot Pract. 2007;8:234-42.
6. Grover SA, Ho V, Lavoie F, Coupal L, Zowall H, Pilote L. The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins? Arch Intern Med. 2003;163:333-9.
7. Wu EQ, Birnbaum HG, Mareva M, Tuttle E, Castor AR, Jackman W, et al. Economic burden and co-morbidities of atrial fibrillation in a privately insured population. Curr Med Res Opin. 2005;21:1693-9.
8. Johnston SS, Curkendall S, Makenbaeva D, Mozaffari E, Goetzel R, Burton W, et al. The direct and indirect cost burden of acute coronary syndrome. J Occup Environ Med. 2011;53:2-7.
9. Goetzel RZ, Long SR, Ozminkowski RJ, Hawkins K, Wang S, Lynch W. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U.S. employers. J Occup Environ Med. 2004;46:398-412.
10. Liu JLY, Maniadakis N, Gray A, Rayner M. The economic burden of coronary heart disease in the UK. Heart. 2002;88:597-603.
11. Luengo-Fernandez R, Leal J, Gray A, Peterson S, Rayner M. Cost of cardiovascular diseases in the United Kingdom. Heart. 2006;92:1384-9.
12. Zhao Z, Winget M. Economic burden of illness of acute coronary syndromes: medical and productivity costs. BMC Health Serv Res. 2011;11:35.
13. Bernheim SM, Grady JN, Lin Z, Wang Y, Wang Y, Savage SV, et al. National patterns of risk-standardized mortality and readmission for acute myocardial infarction and heart failure. Update on publicly reported outcomes measures based on the 2010 release. Circ Cardiovasc Qual Outcomes. 2010;3:459-67.
14. Milani RV, Lavie CJ. Impact of worksite wellness intervention on cardiac risk factors and one-year health care costs. Am J Cardiol. 2009;104:1389-92.
15. Anderson D, Whitmer R, Goetzel R, Ozminkowski R, Wasserman J, Serxner S. The relationship between modifiable health risks and group-level health care expenditures. Am J Health Promot. 2000;15:45-52.
16. Burton W, Chen C, Conti D, Schultz A, Edington D. Measuring the relationship between employees' health risk factors and corporate pharmaceutical expenditures. J Occup Environ Med. 2003;45:793-802.
17. Goetzel R, Anderson D, Whitmer R, Ozminkowski R, Dunn R, Wasserman J. The relationship between modifiable health risks and health care expenditures: an analysis of themulti-employerHEROhealth risk and cost database. JOccup Environ Med. 1998;40:843-54.
18. Yen L, Schultz A, Schnueringer E, Edington D. Financial costs due to excess health risks among active employees of a utility company. J Occup Environ Med. 2006;48:896-905.
19. Yen L, Edington D, Witting P. Associations between health risk appraisal scores and employee medical claims costs in a manufacturing company. Am J Health Promot. 1991;6:46-54.
20. Boles M, Pelletier B, Lynch W. The relationship between health risks and work productivity. J Occup Environ Med. 2004;46:737-45.
21. Serxner SA, Gold DB, Bultman KK. The impact of behavioral health risks on worker absenteeism. J Occup Environ Med. 2001;43:347-54.
22. Alavinia SM, Molenaar D, Burdorf A. Productivity loss in the workforce: associations with health, work demands, and individual characteristics. Am J Ind Med. 2009;52:49-56.
23. Burton W, Chen C, Conti D, Schultz A, Pransky G, Edington D. The association of health risks with on-the-job productivity. J Occup Environ Med.
24. Grossmeier J, Mangen DJ, Terry PE, Haglund-Howieson L. Health risk as a predictor of productivity change. J Occup Environ Med. 57:347-354.
25. Pelletier B, Boles M, Lynch W. Change in health risks and work productivity over time. J Occup Environ Med. 2004;46:746-54.
26. Allen LA, Tomic KE, Wilson KL, Smith DM, Agodoa I. The inpatient experience and predictors of length of stay for patients hospitalized with systolic heart failure: comparison by commercial, medicaid, and medicare payer type. J Med Econ. 2013;16:43-54.
27. Carls GS, Roebuck MC, Brennan TA, Slezak JA, Matlin OS, Gibson TB. Impact of medication adherence on absenteeism and short-term disability for five chronic diseases. J Occup Env Med. 2012;54:792-805.
28. Epstein AJ, Groeneveld PW, Harhay MO, Yang F, Polsky D. Impact of minimally invasive surgery on medical spending and employee absenteeism. JAMA Surg. 2013;148:641-7.
29. Ye X, Qian C, Liu J, St Peter WL. Lower risk of major cardiovascular events associated with adherence to colesevelam HCl. Pharmacotherapy. 2013;33:1062-70.
30. Hansen LG, Danielson E. Health research data for the real world: The MarketScan® Databases [White paper]. Available at: http://truvenhealth.com/Portals/0/Users/031/31/31/PH-13434%200314-MarketScan-WP-web.pdf. Accessed June 19, 2015.
31. Shenolikar R, Song X, Anderson JA, Chu BC, Cantrell R. Costs of asthma among US working adults. Am J Manag Care. 2011;17(6):409-16.
32. Song X, Shi N, Badamgarav E, Kallich J, Varker H, Lenhart G, et al. Cost burden of second fracture in the US health system. Bone. 2011;48(4):828-36.
33. Current Population Survey. 2010 Annual Social and Economic (ASEC) Supplement / conducted by the Bureau of the Census for the Bureau of Labor Statistics. Washington: Bureau of the Census [producer and distributor; 2010.
34. The basics of short-term disability insurance. Available at: http://www.insure.com/articles/disabilityinsurance/short-term-disability.html. Accessed June 19, 2015.
35. Austin PC. The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies. Stat Med. 2010;29:2137-48.
36. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46:399-424.
37. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-9.
38. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10:150-61.
39. Bitton R. The economic burden of osteoarthritis. Am J Manag Care. 2009;15:S230-5.
40. Pike C, Birnbaum HG, Schiller M, Sharma H, Burge R, Edgell ET. Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US. Pharmacoeconomics. 2010;28:395-409.
41. Bonafede M, Espindle D, Bower AG. The direct and indirect costs of long bone fractures in a working age US population. J Med Econ. 2013;16:169-78.
42. Chapman RH, Liu LZ, Girase PG, Straka RJ. Determining initial and follow-up costs of cardiovascular events in a US managed care population. BMC Cardiovasc Disord. 2011;11:11.
43. O'Sullivan AK, Rubin J, Nyambose J, Kuznik A, Cohen DJ, Thompson D. Cost estimation of cardiovascular disease events in the US. Pharmacoeconomics. 2011;29:693-704.
44. Arena R, Guazzi M, Briggs PD, Cahalin LP, Myers J, Kaminsky LA, et al. Promoting health and wellness in the workplace: a unique opportunity to establish primary and extended secondary cardiovascular risk reduction programs. Mayo Clin Proc. 2013;88:605-17.
45. Bouillon K, Singh-Manoux A, Jokela M, Shipley MJ, Batty GD, Brunner E, et al. Decline in low-density lipoprotein cholesterol concentration: lipid-lowering drugs, diet, or physical activity? Evidence from the Whitehall II study. Heart. 2011;97:923-30.
46. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;Nov 7. doi: 10.1016/j.jacc.2013.11.002. [Epub ahead of print].
47. Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3xsum.pdf. Accessed June 19, 2015.
48. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-81.
49. Song X, Fowler R, Ruiz R, Hurley D, Barron R. Impact of neutropenic complications on short-term disability in patients with cancer receiving chemotherapy. J Med Econ. 2009;12(2):154-63.
50. Song X, Huse D, William S, Borok G, McDonough K, Ozminkowski R. A projection of lipid-lowering therapy on high-risk employee disability and medical costs. J Occup Environ Med. 2006;48(10):1014-22.
51. Johns G. Presenteeism in the workplace: a review and research agenda. J Organ Behav. 2010;31:519-42.
52. Economic News Release, Table 8, Private Industry, by Establishment Employment Size. United States Department of Labor, The Bureau of Labor Statistics. Available at: http://www.bls.gov/news.release/ecec.t08.htm. Accessed June 19, 2015.